X
KEY PRODUCTS
Details:
Under the agreement, Eton Pharmaceuticals has acquired U.S. marketing rights to carglumic acid tablets. The product is an AB-rated, substitutable generic version of Carbaglu®.
Lead Product(s): Carglumic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2021
Details:
Novitium Pharma's lead drug, Acyclovir oral suspension, is a synthetic nucleoside analogue active against herpesviruses. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV.
Lead Product(s): Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ANI Pharmaceuticals Inc
Deal Size: $372.5 million Upfront Cash: $89.5 million
Deal Type: Acquisition March 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
